Active — Not RecruitingNot Applicable

TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients

Egypt60 participantsStarted 2025-10-20

Plain-language summary

This study investigates the relationship between Transient Receptor Potential Melastatin 2 (TRPM2) gene polymorphism and Nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome expression in patients with vitiligo. Vitiligo is a common autoimmune depigmenting disorder characterized by melanocyte destruction associated with oxidative stress and immune dysregulation. TRPM2 is a calcium-permeable cation channel activated by oxidative stress, while NLRP3 inflammasome activation promotes inflammation through interleukin-1β (IL-1β) and interleukin-18 (IL-18) release. This study aims to evaluate TRPM2 genetic variants, NLRP3 expression levels, and their possible correlation with disease severity measured using the Vitiligo Area Scoring Index (VASI).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Adult patients (aged 18 years and older) clinically diagnosed with vitiligo, either newly diagnosed or not on treatment for at least 3 months before the study. Exclusion Criteria: * Any participant with associated inflammatory disease (such as infections or autoimmune disorders). * Patients with chronic diseases including cardiac, hepatic, hematologic, or renal disorders, or malignancies. * Patients who had recent major surgical procedures. * Patients with segmental vitiligo. * Vitiligo patients who have received treatment within 3 months prior to the study.

What they're measuring

TRPM2 gene polymorphism in vitiligo patients

Timeframe: At time of enrollment (single visit)

Trial details

NCT IDNCT07232238

SponsorAswan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-10-01